|
||
| The Copaxone News Channel |  |
|
|
|||||
|
|||||
|
|||||
| MS NEWS ARCHIVES: by week | |||||
| March 2005 | |||||
| June 2005 | |||||
| July 2005 | |||||
| August 2005 | |||||
| October 2005 | |||||
| November 2005 | |||||
| December 2005 | |||||
| January 2006 | |||||
| February 2006 | |||||
| May 2006 | |||||
| June 2006 | |||||
| August 2006 | |||||
| October 2006 | |||||
| November 2006 | |||||
| December 2008 | |||||
| January 2013 | |||||
| May 2013 | |||||
| June 2013 | |||||
| July 2013 | |||||
| September 2013 | |||||
| October 2013 | |||||
| November 2013 | |||||
| November 2014 | |||||
| December 2014 | |||||
| January 2015 | |||||
| March 2015 | |||||
| April 2015 | |||||
| May 2015 | |||||
| July 2015 | |||||
| February 2016 | |||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
| HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS | |||||
 |
|||||
| |||||
| |||||
 Click to view 1280 MS Walk photos! | |||||
|
|||||
|
|||||
|
|||||
Monday
COPAXONE: "Study Showed Treatment with COPAXONE(R) is Associated with Significantly Fewer Days Missed from Work in MS Patients.."Non-Treatment and Treatment with Avonex or Betaseron Had No Significant Impact on Days Missed"..CLICK FOR MORE
"A retrospective analysis of multiple sclerosis (MS) patients comparing patients treated with immunomodulatory agents with untreated patients revealed that only treatment with COPAXONE(R) (glatiramer acetate injection) was associated with significantly fewer days missed from work compared to untreated patients. Neither treatment with Avonex(R) (Interferon beta-1a IM) nor Betaseron(R) (Interferon beta-1b) was associated with significantly fewer days missed from work in comparison to untreated patients. The findings of this study, "Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis," were published in the September issue of the journal WORK.
"Being able to pursue a satisfying work life is an important part of life for most people, yet the symptoms of relapsing-remitting multiple sclerosis (RRMS) and the up and down nature of the disease can make this a challenge for many patients," said MerriKay Oleen-Burkey, PhD, director of Outcomes Research at Teva Neuroscience and a study investigator. "After diagnosis, an estimated 70 to 80 percent of MS patients in the United States leave the workforce. A major goal in the treatment of RRMS is to reduce disease relapses and to provide patients the ability to go on with their lives despite the disease."
Disease relapses in MS can be associated with hospitalization, interference with employment and accumulated disability, leading researchers to suggest that reducing relapse rates may be associated with a reduction in lost work time.
"The results of this study suggest that COPAXONE(R) might be a contributor in helping to keep MS patients participating in the workplace for as long as possible," said Oleen-Burkey. "It is important to consider the results of this study in context given various study limitations, including the retrospective design and a relatively small sample size. It is also important to continue searching for the optimal combination of factors for preserving the working life of MS patients....":
"A retrospective analysis of multiple sclerosis (MS) patients comparing patients treated with immunomodulatory agents with untreated patients revealed that only treatment with COPAXONE(R) (glatiramer acetate injection) was associated with significantly fewer days missed from work compared to untreated patients. Neither treatment with Avonex(R) (Interferon beta-1a IM) nor Betaseron(R) (Interferon beta-1b) was associated with significantly fewer days missed from work in comparison to untreated patients. The findings of this study, "Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis," were published in the September issue of the journal WORK.
"Being able to pursue a satisfying work life is an important part of life for most people, yet the symptoms of relapsing-remitting multiple sclerosis (RRMS) and the up and down nature of the disease can make this a challenge for many patients," said MerriKay Oleen-Burkey, PhD, director of Outcomes Research at Teva Neuroscience and a study investigator. "After diagnosis, an estimated 70 to 80 percent of MS patients in the United States leave the workforce. A major goal in the treatment of RRMS is to reduce disease relapses and to provide patients the ability to go on with their lives despite the disease."
Disease relapses in MS can be associated with hospitalization, interference with employment and accumulated disability, leading researchers to suggest that reducing relapse rates may be associated with a reduction in lost work time.
"The results of this study suggest that COPAXONE(R) might be a contributor in helping to keep MS patients participating in the workplace for as long as possible," said Oleen-Burkey. "It is important to consider the results of this study in context given various study limitations, including the retrospective design and a relatively small sample size. It is also important to continue searching for the optimal combination of factors for preserving the working life of MS patients....":